Xiamen Yunzi Equity Investment Partnership Enterprise (Limited Partnership) acquired 7.05% stake in LBP Medicine Science & Technology Co., Ltd from Shenzhen Jinyin Zhongxin Investment Development Co., Ltd. for approximately CNY 140 million.
January 20, 2017
Share
Xiamen Yunzi Equity Investment Partnership Enterprise (Limited Partnership) agreed to acquire 7.05% stake in LBP Medicine Science & Technology Co., Ltd. from Shenzhen Jinyin Zhongxin Investment Development Co., Ltd. for approximately CNY 140 million on September 5, 2016. Xiamen Yunzi Equity Investment Partnership deposited CNY 3 million and has to transfer remaining payment of CNY 138 million to the designated account of Jingdezhen Intermediate People’s Court before September 25, 2016. As on November 30, 2016, LBP reported total assets of CNY 360.76 million and owner's equity of CNY 324.07 million.
Xiamen Yunzi Equity Investment Partnership Enterprise (Limited Partnership) completed the acquisition of 7.05% stake in LBP Medicine Science & Technology Co., Ltd. from Shenzhen Jinyin Zhongxin Investment Development Co., Ltd. on October 20, 2016.
Guangzhou LBP Medicine Science & Technology Co Ltd is a China-based company mainly engaged in the research, development, production and sales of in vitro diagnostic reagents and instruments. The Companyâs main products are pathological diagnostic reagents and instruments, covering three major technology platforms for cytological diagnosis, molecular diagnosis and immunodiagnosis, including LBP series, IHC series, PCR series and FISH series, such as integrated slide and dyeing machine, liquid-based cell and microorganism processing, preservation reagents, automatic nucleic acid molecular hybridization instrument, automatic slide processing system and immunochromogenic reagents, etc. Its products are mainly used in pathological diagnosis of tumors. The Company operates its businesses within the domestic market and to overseas markets.
GUANGZHOU LBP MEDICINE SCIENCE & TECHNOLOGY CO., LTD. 
